Location History:
- Weesp, BE (2007)
- Weesp, NL (2005 - 2008)
Company Filing History:
Years Active: 2005-2008
Title: Willy Deleersnijder: Innovator in G-Protein Coupled Receptors
Introduction
Willy Deleersnijder is a prominent inventor based in Weesp, Netherlands. He has made significant contributions to the field of biotechnology, particularly in the area of G-protein coupled receptors. With a total of 8 patents to his name, his work has advanced our understanding of these critical biological systems.
Latest Patents
Deleersnijder's latest patents include groundbreaking inventions related to the G-protein coupled receptor family. One notable patent is for a binding assay employing IGS4, which involves novel identified polynucleotides and polypeptides. This invention focuses on the inhibition or activation of these polynucleotides and polypeptides, as well as methods for screening compounds that act as agonists or antagonists of the IGS family. Another significant patent involves a polynucleotide and expression system for a novel human G-protein coupled receptor, also related to the IGS4 family. Both patents highlight the high affinity binding of neuropeptides known as neuromedin U to the IGS4 polypeptides.
Career Highlights
Throughout his career, Willy Deleersnijder has worked with notable companies such as Solvay Pharmaceuticals, B.V. and Solvay Pharmaceuticals, GmbH. His experience in these organizations has allowed him to collaborate on various innovative projects that have contributed to advancements in pharmaceutical research and development.
Collaborations
Deleersnijder has collaborated with several professionals in his field, including Rico Wiegers and Michael Weske. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Willy Deleersnijder's contributions to the field of G-protein coupled receptors have made a lasting impact on biotechnology. His patents and collaborations reflect his dedication to advancing scientific knowledge and innovation.